Analysts from TheStreet believe Parsippany-Troy Hills, N.J.-based Allergan's CEO Brett Saunders hinted the company would soon shift away from early-stage pipeline acquisitions to focus instead on research and development acquisition.
Here's what you should know.
1. Mr. Saunders presented at the 35th annual J.P. Morgan Healthcare Conference where he said the company has a goal "to have a very strong balance between R&D deals and accretive deals."
2. Allergan announced its intent to acquire LifeCell Corp. for $2.9 billion on Dec. 20, 2016.
It also recently bought out Vitae Pharmaceuticals for $639 million.
3. Mr. Saunders said the company's six therapies currently in phase 3 development could be worth up to $13 billion in peak sales.
4. Between 2016 and 2017, Allergan plans to launch 11 new products. Predictions say the launches could generate approximately $5 billion in sales for the company.